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This is one of a series of BMJ summaries of new guidelines, which are
based on the best available evidence; they highlight important
recommendations for clinical practice, especially where uncertainty or
controversy exists.
Why read this summary?
Breast cancer is the commonest cancer in women, with over 40
500 new cases diagnosed each year in England and Wales.
1 2
Despite a steady decline in age standardised mortality rates
owing to screening and better management, the disease still
causes 10 900 deaths each year in England and Wales,
1 2 with
a huge social and emotional impact. This article outlines the
most important recent recommendations from the National
Institute for Health and Clinical Excellence (NICE) on the
diagnosis and treatment of early and locally advanced breast
cancer.
3
Recommendations
NICErecommendationsarebasedonsystematicreviewsofbest
available evidence. When minimal evidence is available,
recommendations are based on the Guideline Development
Group’s opinion of what constitutes good practice. Evidence
levels for the recommendations are given in italic in square
brackets.
Thisnewguidelinecoverswomenpresentingwithbreastcancer
in whom the primary tumour may have been non-palpable and
detected by screening mammography through to women with
cancers over 5 cm but in whom there is no evidence of spread
beyond the breast and axillary lymph nodes. The guideline
includes a large spectrum of disease, ranging from ductal
carcinoma in situ (DCIS) to inflammatory breast cancer, and
also includes breast cancer in men, which is rare. Advanced
breast cancer is the subject of another guideline.
4
Diagnosis and preoperative assessment
• Magnetic resonance imaging (MRI) of the breast is not
recommended as a routine preoperative assessment of
patients with invasive breast cancer or DCIS but can help
when a discrepancy exists between the clinical and
radiological assessment, when breast density prevents
mammographic assessment, or when breast conservation
surgerytoassesstumoursizeisbeingconsideredinlobular
cancer. [Based on moderate quality evidence from
case-controlandcaseseriesstudiesandontheexperience
of the Guideline Development Group]
• Ensure that pretreatment ultrasonography of the axilla is
carried out and ultrasound guided needle biopsy also if
abnormal lymph nodes are detected. [Based on moderate
quality clinical evidence from case series studies that
informed an economic analysis of cost effectiveness]
Psychological support
• Members of the breast cancer clinical team should have
completed an approved communication skills training
programme.
• Allocate patients to a named breast care nurse specialist to
support them throughout their care and follow-up.
• Ensure that specialist psychological support, including
psychiatric services, is readily available when necessary.
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Practice
PRACTICESurgery to the breast and axilla
Surgery is the primary treatment for DCIS and early invasive
breastcancer,preferablywithbreastconservationwhenpossible.
• AfterbreastconservingsurgeryforDCISaminimumradial
margin of excision of 2 mm is recommended, with
pathological examination in line with the reporting
standards of the NHS breast screening programme. If the
margin is less than 2 mm consider re-excision after
discussing the risks and benefits with the patient. Enter
patients with screen detected DCIS into the Sloane Project
(the UK prospective audit of screen detected non-invasive
carcinomas of the breast).
5 Breast units should audit their
recurrence rates.
• When no evidence exists of lymph node involvement by
ultrasonography or a negative ultrasound guided biopsy,
the axilla should be staged by minimal surgery, preferably
sentinel lymph node biopsy, rather than lymph node
clearance. Perform sentinel lymph node biopsy using the
dual technique with isotope and blue dye. Breast units
should audit their axillary recurrence rates. [Based on an
overall moderate quality of evidence from randomised
controlled trials, case series, and a meta-analysis of case
series studies]
• Further axillary treatment, preferably by lymph node
dissection as it gives additional staging information, is
requiredifmacrometastasesormicrometastasesarepresent
in the sentinel lymph node or if there is histologically
provedcancerinthepreoperativeultrasoundguidedneedle
biopsy. Patients with isolated tumour cells in the sentinel
nodes should have no further axillary surgery as they are
regarded as lymph node negative.
• Discuss immediate breast reconstruction with all patients
for whom mastectomy is advised, unless they have
significant comorbidity or where adjuvant therapy may be
compromised, and discuss the full choice of the different
types of breast reconstruction, whether available locally
or not. [Based on low quality evidence from observational
studiesandontheexperienceoftheGuidelineDevelopment
Group]
Planning adjuvant treatment
• Measure the oestrogen receptor status of all invasive
cancers using immunohistochemistry and report this
quantitatively. The routine measurement of the
progesterone receptor status is not needed. Assess the
human epidermal growth factor receptor 2 status by using
a standardised and qualitatively assured method. Ensure
these results are available and recorded at the
multidisciplinaryteammeetingtoguideadjuvanttreatment
decisions.
• Consideradjuvanttherapyatthemultidisciplinarymeeting
for all patients with invasive breast cancer after surgery,
taking into account the prognostic and predictive factors,
the potential benefits and side effects, and the outcome of
discussions with the patient.
• The web based tool Adjuvant! Online
6 is useful for
estimating the absolute benefit of adjuvant treatment for
an individual.
• Start chemotherapy or radiotherapy as soon as possible
within 31 days of completion of surgery.
7 [Based on the
experience of the Guideline Development Group and the
recommendations in the Department of Health’s cancer
reform strategy
7 ]
Endocrine therapy in invasive disease
• For postmenopausal patients with oestrogen receptor
positive invasive breast cancer that is not considered to be
low risk, offer an aromatase inhibitor, either anastrozole
or letrozole, as initial adjuvant therapy. If tamoxifen was
chosen as the primary adjuvant treatment an aromatase
inhibitor, either exemestane or anastrozole, can be offered
aftertwotothreeyearsoftamoxifen,orletrozoleafterfive
yearsoftamoxifeninhigherriskpatients.Whenaromatase
inhibitors are poorly tolerated or contraindicated as the
primary adjuvant treatment, tamoxifen should be given.
[Based on high quality randomised controlled trials]
Trastuzumab therapy
• After surgery, chemotherapy and radiotherapy (when
applicable) in patients who have breast cancer that is
positiveforhumanepidermalgrowthfactorreceptor2and
who have satisfactory cardiac function, offer trastuzumab
everythreeweeksforoneyearoruntildiseaseprogression.
Trastuzumab is a humanised monoclonal antibody that
targets the human epidermal growth factor receptor 2,
which is overexpressed in about 15% of breast cancers.
Periodic follow-up of cardiac function during the year is
mandatory.
Managing bone health
• Offer baseline dual energy x ray absorptiometry to assess
bonemineraldensityinpatientsstartingaromataseinhibitor
treatment, those who have had treatment induced
menopause, or those having ovarian ablation or
suppression,asallthesetreatmentscancauseconsiderable
bonelossandconsequentriskoffracture.[Basedonahigh
quality guideline
8 and the experience of the Guideline
Development Group]
• Offer bisphosphonates to patients according to UK
consensus guidance for managing breast cancer treatment
induced bone loss.
8
Adjuvant radiotherapy
• Recommend breast radiotherapy after breast conservation
surgery in patients with invasive disease, and consider it
after surgery for DCIS.
• Aftermastectomy,discusschestwallradiotherapyinhigher
risk patients, mainly depending on lymph node
involvement.
• A dose of 40 Gy in 15 fractions using external beam
radiotherapy is recommended.
• Do not irradiate the nodal areas routinely.
Primary systemic therapy
• Endocrinetherapyaloneratherthanprimarysurgeryisnot
appropriate unless surgery is contraindicated. [Based on a
Cochrane review of moderate quality randomised
controlled trials]
• After preoperative chemotherapy for locally advanced or
inflammatory breast cancer, offer mastectomy followed
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PRACTICEby radiotherapy. It would be exceptional to perform breast
conservation.
Complications of local treatment and
menopausal symptoms
• Provide patients with information before surgery or
radiotherapy on the risk of lymphoedema and factors such
as infection that may cause or exacerbate it, including
postoperative physiotherapy regimens. If lymphoedema
develops ensure rapid access to a lymphoedema service.
• Discontinue hormone replacement therapy in all patients
diagnosed with invasive breast cancer, and do not offer it
routinelytowomenwithmenopausalsymptomswhohave
a previous history of the disease. Offer support, written
information, and counselling for those women who might
develop menopausal symptoms as a result of their
treatment.
Follow-up
• AftertreatmentforinvasivecancerandDCIS,offerannual
mammographyforfiveyearstoallpatients.[Basedonlow
to moderate quality evidence from observational studies
and on the experience of the Guideline Development
Group] The frequency of screening after this should be
stratified according to risk by the NHS breast screening
programme (England) and Breast Test Wales.
• Discuss clinical follow-up (which can be in primary,
secondary, or shared care) with the patient. Provide an
agreedwrittencareplanincludingdetailsofthedesignated
named healthcare professionals, dates for review of any
adjuvanttherapyandsurveillancemammography,andother
contacts such as the lymphoedema service. [Based on the
experience of the Guideline Development Group]
Overcoming barriers
Thechallengeforcliniciansandcommissionersisapplyingthis
guideline in a way that provides informed choice and equity of
access to services for all patients. Resources in training and
infrastructure may be needed for the wider use of ultrasound
and mammographic follow-up and will be necessary for
identifying and supporting centres offering specialist MRI
services.Allwomenadvisedtohaveamastectomyneedadvice
on the appropriateness, timeliness, and types of reconstructive
procedures from oncoplastic specialists, who may have to
network across sites. For those whose treatments affect bone
health,accesstosurveillanceandearlyinterventionareessential
toreduceseriouscomplications;thiswillrequirecommissioner
support to acquire scan time for dual energy x ray
absorptiometry.
Many of these recommendations have cost implications. A
costing tool developed by NICE is available, and an
implementation pack will be available soon. Most of the
recommendations can be implemented and audited by the
multidisciplinary breast cancer teams under the supervision of
the cancer networks.
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PRACTICEFurther information on the guidance
Current areas of inconsistency
How follow-up for patients with early and locally advanced breast cancer should be carried out has been controversial for many years. The
existing NICE service guidance for “improving outcomes in breast cancer”
9 recommends that hospital based follow-up after treatment for
early breast cancer should be limited to three years. However, peer review has shown considerable variation across England and Wales in
implementing this recommendation
3 and has led to uncertainty about who should undertake follow-up and where it should be performed.
There is great variation and conflicting advice on follow-up mammography. The new guideline has given clear advice on what individual
breast cancer multidisciplinary teams should now do.
Immediate versus delayed breast reconstruction has been debated for several years. For patients who are concerned about loss of body
image, immediate reconstruction has the advantage of a single breast procedure and fewer operations to obtain an acceptable and usually
good cosmetic outcome. However, a large quantity of information about reconstruction has to be discussed with patients for them to make
informed decisions, and this can be difficult when at the same time absorbing the diagnosis of breast cancer. Furthermore, all methods of
reconstruction have potential complications that might delay subsequent adjuvant therapy. The guideline makes a sensible and pragmatic
recommendation that will give more choice to patients with breast cancer who want reconstruction.
Methods
The development of this guideline was based on methods outlined by the NICE guidelines manual.
10
Four different versions of the guideline have been produced: a full version containing all the evidence and the recommendations; a quick
reference guide; a version known as the “NICE guideline,” which lists the recommendations; and a lay translation of the NICE guideline for
patients and the public. All the versions are available on the NICE website (www.nice.org.uk/CG80).
Future updates of the guideline will be produced as part of the NICE guideline development programme.
10
Future research and remaining uncertainties
The Guideline Development Group also made the following research recommendations.
• What is the effectiveness of cognitive behavioural therapy compared with other psychological interventions for patients with breast
cancer?
• In the absence of good data comparing clinical outcomes between axillary radiotherapy and complete axillary lymph node dissection,
entry into appropriate clinical trials (such as AMAROS (after mapping of the axilla: radiotherapy or surgery), a randomised controlled
trial) is recommended for patients with early breast cancer when sentinel lymph node biopsy shows metastasis in the axilla.
• How effective is trastuzumab in patients with invasive breast cancer: (a) as adjuvant therapy without chemotherapy and (b) as primary
systemic treatment, in terms of quality of life, side effects, disease recurrence rates, disease-free survival, and overall survival? In
patients who are also receiving or have completed chemotherapy, what is the most effective scheduling and duration of treatment
with trastuzumab?
• In patients with early invasive breast cancer, how effective are (a) different hypofractionation radiotherapy regimens, (b) partial breast
radiotherapy, and (c) newer radiotherapy techniques (including intensity modulated radiotherapy), in terms of long term outcomes
such as quality of life, side effects, disease recurrence rates, disease-free survival, and overall survival?
• For patients who have been treated for early invasive breast cancer or DCIS, what is the optimal frequency and length of surveillance
of follow-up mammography?
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PRACTICE